HK1074750A1 - Stable liquid pharmaceutical formulation of igg antiboddies - Google Patents

Stable liquid pharmaceutical formulation of igg antiboddies

Info

Publication number
HK1074750A1
HK1074750A1 HK05107139A HK05107139A HK1074750A1 HK 1074750 A1 HK1074750 A1 HK 1074750A1 HK 05107139 A HK05107139 A HK 05107139A HK 05107139 A HK05107139 A HK 05107139A HK 1074750 A1 HK1074750 A1 HK 1074750A1
Authority
HK
Hong Kong
Prior art keywords
monoclonal antibody
humanized anti
pharmaceutical formulation
liquid pharmaceutical
formulation
Prior art date
Application number
HK05107139A
Other languages
English (en)
Inventor
Elizabet Kaisheva
Supriya Gupta
Shanti Duvur
Malathy Subramanian
Original Assignee
Protein Design Labs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs filed Critical Protein Design Labs
Publication of HK1074750A1 publication Critical patent/HK1074750A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
HK05107139A 2001-11-08 2005-08-17 Stable liquid pharmaceutical formulation of igg antiboddies HK1074750A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33750901P 2001-11-08 2001-11-08
PCT/US2002/036093 WO2003039485A2 (en) 2001-11-08 2002-11-08 Stable liquid pharmaceutical formulation of igg antibodies

Publications (1)

Publication Number Publication Date
HK1074750A1 true HK1074750A1 (en) 2005-11-25

Family

ID=23320826

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05107139A HK1074750A1 (en) 2001-11-08 2005-08-17 Stable liquid pharmaceutical formulation of igg antiboddies

Country Status (17)

Country Link
US (3) US20030138417A1 (el)
EP (1) EP1441589B1 (el)
JP (2) JP5290489B2 (el)
KR (1) KR100913714B1 (el)
CN (1) CN1292655C (el)
AT (1) ATE556591T1 (el)
AU (1) AU2002363339B2 (el)
CA (1) CA2466034C (el)
CY (1) CY2016044I2 (el)
DK (1) DK1441589T3 (el)
ES (1) ES2392073T3 (el)
HK (1) HK1074750A1 (el)
IL (2) IL161677A0 (el)
LU (1) LU93314I2 (el)
NZ (1) NZ532896A (el)
PT (1) PT1441589E (el)
WO (1) WO2003039485A2 (el)

Families Citing this family (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
PT1324776E (pt) * 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US20030138417A1 (en) * 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
AU2003251592A1 (en) * 2002-06-21 2004-01-06 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
WO2004055164A2 (en) * 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
US20040208870A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
AU2004216298B2 (en) 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
PT1610820E (pt) * 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
EP2186527A1 (en) * 2003-11-28 2010-05-19 Micromet AG Compositions comprising polypeptides
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
PE20051053A1 (es) 2004-01-09 2005-12-12 Pfizer ANTICUERPOS CONTRA MAdCAM
US20060008415A1 (en) * 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008523815A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
EP1841456A2 (en) * 2005-01-28 2007-10-10 Wyeth Stabilized liquid polypeptide formulations
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
AU2014240252B2 (en) * 2005-03-08 2016-10-06 Pfizer Products Inc Anti-CTLA-4 Antibody Compositions
JP5670004B2 (ja) * 2005-03-08 2015-02-18 ファイザー・プロダクツ・インク 抗ｃｔｌａ−４抗体組成物
AU2012200203B2 (en) * 2005-03-08 2014-07-03 Pfizer Products Inc. Anti-CTLA-4 Antibody Compositions
HUE034109T2 (en) 2005-03-25 2018-01-29 Regeneron Pharma VEGF antagonist formulations
MX2007014148A (es) * 2005-05-19 2008-01-11 Amgen Inc Composiciones y metodos para incrementar la estabilidad de anticuerpos.
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
KR20080025174A (ko) * 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
CA2615731A1 (en) * 2005-07-29 2007-02-08 Amgen Inc. Formulations that inhibit protein aggregation
EP1917030A4 (en) * 2005-08-03 2011-03-09 Immunogen Inc IMMUNKONJUGATFORMULIERUNGEN
US20100209437A1 (en) * 2005-09-12 2010-08-19 Greg Elson Anti-CD3 Antibody Fromulations
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
EP1951757B1 (en) * 2005-10-06 2014-05-14 Xencor, Inc. Optimized anti-cd30 antibodies
EP1962907A2 (en) * 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof
CA2637726C (en) 2006-01-25 2014-04-15 Taro Pharmaceuticals North America, Inc. Anti-histamine compositions and use thereof
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
KR20090005315A (ko) 2006-04-05 2009-01-13 애보트 바이오테크놀로지 리미티드 항체 정제
AU2007239679B2 (en) 2006-04-13 2012-10-11 Chugai Seiyaku Kabushiki Kaisha Taurine transporter gene
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
JP5290152B2 (ja) 2006-04-21 2013-09-18 ノバルティス アーゲー 拮抗剤抗ｃｄ４０抗体薬学的組成物
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2014268186C1 (en) * 2006-04-26 2017-12-07 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US7608261B2 (en) 2006-06-16 2009-10-27 Regeneron Pharmacuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
AU2012200284B2 (en) * 2006-10-06 2014-03-06 Amgen Inc. Stable Antibody Formulations
PE20081179A1 (es) * 2006-10-06 2008-09-29 Amgen Inc Formulaciones estables de anticuerpos egfr
AU2007309616B2 (en) * 2006-10-20 2011-10-06 Amgen Inc. Stable polypeptide formulations
ES2748526T3 (es) * 2006-12-21 2020-03-17 Amgen Inc Formulaciones tamponadas estables que contienen polipéptidos
WO2008114673A1 (ja) 2007-03-15 2008-09-25 Chugai Seiyaku Kabushiki Kaisha ポリペプチドの製造方法
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP2010532790A (ja) * 2007-07-06 2010-10-14 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗体処方
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
MX2010001319A (es) 2007-08-07 2010-06-01 Chugai Pharmaceutical Co Ltd Metodo para producir proteinas heterogeneas.
AR068564A1 (es) 2007-09-26 2009-11-18 Chugai Pharmaceutical Co Ltd Anticuerpo anti- receptor de il-6 (interleuquina 6)
EP4339294A2 (en) 2007-09-26 2024-03-20 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
CA3139492A1 (en) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
WO2009051109A1 (ja) 2007-10-15 2009-04-23 Chugai Seiyaku Kabushiki Kaisha 異種タンパク質を高生産する細胞の作製方法
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2213746B1 (en) * 2007-10-24 2015-07-15 Chugai Seiyaku Kabushiki Kaisha Cell for use in the production of exogenous protein, and production process using the cell
US8796206B2 (en) * 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US20110014203A1 (en) * 2007-12-28 2011-01-20 Fredrik Nilsson Formulation
EP2328607A1 (en) 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
CN102159194A (zh) * 2008-09-19 2011-08-17 霍夫曼-拉罗奇有限公司 新抗体制剂
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
JP2012510468A (ja) * 2008-11-28 2012-05-10 アボット・ラボラトリーズ 安定な抗体組成物およびこれを安定させるための方法
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US10005830B2 (en) 2009-03-05 2018-06-26 Ablynx N.V. Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
AR076640A1 (es) * 2009-03-06 2011-06-29 Genentech Inc Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura
CN102361632A (zh) * 2009-03-30 2012-02-22 弗·哈夫曼-拉罗切有限公司 避免玻璃雾化的方法
US8741601B2 (en) 2009-04-22 2014-06-03 Chugai Seiyaku Kabushiki Kaisha Method for producing a cell capable of high-yield production of heteroproteins
SG175188A1 (en) * 2009-05-04 2011-11-28 Abbott Biotech Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
WO2011008770A2 (en) * 2009-07-14 2011-01-20 Biogen Idec Ma Inc. Methods for inhibiting yellow color and peroxide formation in a composition
CA2726232A1 (en) * 2009-07-16 2010-08-12 Arecor Limited Stable formulation of a therapeutic protein
EP2473851A1 (en) 2009-08-31 2012-07-11 Abbott Biotherapeutics Corp. Use of an immunoregulatory nk cell population for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients
EP3438126B1 (en) * 2009-09-03 2020-08-19 Ablynx N.V. Stable formulations of polypeptides and uses thereof
US20110059079A1 (en) * 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody Coformulations
US8821879B2 (en) 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
US20110104153A1 (en) 2009-10-30 2011-05-05 Facet Biotech Corporation Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients
US20110158987A1 (en) * 2009-12-29 2011-06-30 F. Hoffmann-Laroche Ag Novel antibody formulation
LT2521568T (lt) 2010-01-06 2018-12-10 Dyax Corp. Plazmos kalikreiną surišantys baltymai
US20120294866A1 (en) * 2010-01-19 2012-11-22 F. Hoffmann-La Roche Ag Pharmaceutical formulation for proteins
TWI609698B (zh) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
LT2542257T (lt) 2010-03-01 2017-11-27 Bayer Healthcare Llc Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi)
MX347504B (es) * 2010-03-01 2017-04-28 Cytodyn Inc Formulaciones concentradas de proteina y usos de las mismas.
EP3626263A1 (en) 2010-06-04 2020-03-25 Wyeth LLC Vaccine formulations
FR2961107B1 (fr) * 2010-06-15 2012-07-27 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines stabilisee
AU2011301803A1 (en) * 2010-09-17 2013-03-21 Baxalta GmbH Stabilization of immunoglobulins and other proteins through aqueous formulations with sodium chloride at weak acidic to neutral pH
JO3400B1 (ar) 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
LT2635601T (lt) 2010-11-04 2016-10-10 Boehringer Ingelheim International Gmbh Antikūnai prieš il-23
EP2637690B1 (en) 2010-11-11 2016-09-21 AbbVie Biotechnology Ltd HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS
EP2471554A1 (en) * 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
EP2661450A4 (en) 2011-01-06 2014-04-23 Dyax Corp PROTEINS BINDING TO PLASMA KALLIKREINE
MX349901B (es) 2011-01-13 2017-08-18 Regeneron Pharma Uso de un antagonista de factor de crecimiento endotelial vascular para tratar transtornos oculares angiogenicos.
CN103582700B (zh) 2011-03-25 2016-08-17 弗·哈夫曼一拉罗切有限公司 新的蛋白质纯化方法
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
AR086823A1 (es) * 2011-06-30 2014-01-22 Genentech Inc Formulaciones de anticuerpo anti-c-met, metodos
JP6431372B2 (ja) 2011-10-25 2018-11-28 プロシーナ バイオサイエンシーズ リミテッド 抗体製剤および方法
ES2732243T3 (es) * 2012-02-16 2019-11-21 Santarus Inc Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
JP6293120B2 (ja) * 2012-05-03 2018-03-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ＩＬ−２３ｐ１９抗体
SI2849723T1 (sl) * 2012-05-18 2018-09-28 Genentech, Inc. Formulacije z visoko koncentracijo monoklonskih protiteles
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
MX2015000337A (es) * 2012-07-09 2015-09-25 Coherus Biosciences Inc Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles.
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
JP6463268B2 (ja) 2012-09-07 2019-01-30 コヒラス・バイオサイエンシズ・インコーポレイテッド 安定水性アダリムマブ製剤
EP2727602A1 (en) 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
WO2014141152A2 (en) 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Low concentration antibody formulations
EP3216804A3 (en) 2013-03-15 2017-12-20 AbbVie Biotechnology Ltd. Anti-cd25 antibodies and their uses
CA2904527A1 (en) 2013-03-15 2014-09-18 Abbvie Biotechnology Ltd. Anti-cd25 antibodies and their uses
IL292121B2 (en) 2013-03-15 2024-02-01 Takeda Pharmaceuticals Co Anti-plasma kallikrein antibodies
CN103217525B (zh) * 2013-03-21 2015-04-29 上海执诚生物科技股份有限公司 一种含有提高胱抑素c胶乳包被抗体的稳定性的组合物、稳定剂及其制备方法和用途
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
ES2860480T3 (es) 2013-08-30 2021-10-05 Takeda Gmbh Anticuerpos neutralizantes de GM-CSF para su uso en el tratamiento de la artritis reumatoide o como analgésicos
EP3071237A1 (en) 2013-11-21 2016-09-28 Genmab A/S Antibody-drug conjugate lyophilised formulation
DK3096798T3 (da) 2014-01-21 2021-03-01 Dyax Corp Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem
CA2942713A1 (en) 2014-03-27 2015-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
US11173208B2 (en) * 2014-05-07 2021-11-16 Takeda Gmbh Liquid formulation comprising GM-CSF neutralizing compound
TWI694836B (zh) * 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
SG11201609706VA (en) 2014-06-23 2017-01-27 Novartis Ag Site specific protein modifications
WO2015198199A1 (en) 2014-06-23 2015-12-30 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof.
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
JP2017524359A (ja) 2014-07-24 2017-08-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２３ａ関連疾患の処置に有用なバイオマーカー
MY192824A (en) 2014-09-03 2022-09-12 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
TW201625672A (zh) 2014-10-24 2016-07-16 默沙東藥廠 升糖素及ｇｌｐ－１受體之共促效劑
RS59805B1 (sr) 2014-11-07 2020-02-28 Sesen Bio Inc Unapređena il-6 antitela
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
BR112017014194A2 (pt) 2015-01-23 2018-01-09 Novartis Ag conjugados de ácido graxo de apelina sintéticos com meia-vida melhorada
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
IL282923B2 (en) 2015-05-07 2023-10-01 Novimmune Sa Methods and preparations for diagnosis and treatment of disorders in patients with high levels of chemokine C.-X.-C. Ligand 9 and other biomarkers
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
PL3334747T3 (pl) 2015-08-13 2024-04-02 Amgen Inc. Naładowana filtracja wgłębna białek wiążących antygen
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
EP3384049B1 (en) 2015-12-03 2023-08-02 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
US20170157215A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
IL311156A (en) 2015-12-11 2024-04-01 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and their uses in the treatment of hereditary angioedema attack
EP3393494A1 (en) 2015-12-22 2018-10-31 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP3402465B1 (en) 2016-01-13 2024-03-13 Genmab A/S Formulation for antibody and drug conjugate thereof
MX2018010032A (es) * 2016-02-23 2019-03-11 Sesen Bio Inc Formulaciones de antagonista de il-6 y sus usos.
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
WO2018027195A1 (en) * 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
WO2018075818A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
EP3533441A4 (en) 2016-10-28 2019-12-04 Celltrion Inc. STABLE PHARMACEUTICAL FORMULATION
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
WO2018156367A1 (en) * 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
GB201703062D0 (en) * 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
TW202228779A (zh) * 2017-03-01 2022-08-01 英商梅迪繆思有限公司 抗rsv單株抗體配製物
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372241A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3603669A4 (en) * 2017-03-31 2021-01-06 Meiji Seika Pharma Co., Ltd. Aqueous formulation, aqueous formulation in an injector, antibody protein disaggregation agent, and antibody protein disaggregation method
WO2018193471A1 (en) * 2017-04-18 2018-10-25 Dr. Reddy's Laboratories Limited Stable liquid pharmaceutical composition
MX2019013072A (es) 2017-05-02 2019-12-16 Merck Sharp & Dohme Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN110198739B (zh) * 2017-05-16 2023-04-04 江苏恒瑞医药股份有限公司 一种pd-l1抗体药物组合物及其用途
SG11202000298VA (en) 2017-07-14 2020-02-27 Pfizer Antibodies to madcam
RU2020112302A (ru) 2017-09-05 2021-10-06 Мерк Шарп И Доум Корп. Соединения для уменьшения вязкости биологических композиций
MA50174A (fr) * 2017-09-18 2020-07-29 Amgen Inc Formules de protéines de fusion vegfr-fc
US20200376080A1 (en) 2017-12-22 2020-12-03 Novartis Ag Methods of treating metabolic disorders with fgf21 variants
MX2020011848A (es) 2018-05-10 2021-03-29 Regeneron Pharma Formulaciones que contienen proteína de fusión del receptor de vegf a alta concentración.
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
JP2022513626A (ja) 2018-11-26 2022-02-09 ノバルティス アーゲー Ｌｐｌ－ｇｐｉｈｂｐ１融合ポリペプチド
EP3888678A4 (en) * 2018-11-29 2022-02-16 Harbour Biomed Therapeutics Limited PREPARATION OF AN ANTI-PD-L1 ANTIBODY
WO2020152367A1 (en) 2019-01-25 2020-07-30 Ospedale San Raffaele S.R.L. Inhibitor of dux4 and uses thereof
JP2022540638A (ja) * 2019-07-12 2022-09-16 コントラフェクト コーポレイション 抗体を含む治療用タンパク質製剤及びその使用
GB201913697D0 (en) 2019-09-23 2019-11-06 King S College London DAP10/DAP12 fusion polypeptides
AU2021207632A1 (en) * 2020-01-13 2022-07-07 Aptevo Research And Development Llc Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
GB202003277D0 (en) 2020-03-06 2020-04-22 King S College London Therapeutic agents
JP2023525898A (ja) * 2020-05-19 2023-06-19 エフ． ホフマン－ラ ロシュ アーゲー 非経口タンパク質溶液における可視粒子の形成を防止するためのキレート剤の使用
GB202007655D0 (en) 2020-05-22 2020-07-08 King S College London Chimeric nkg2d protein
AU2022242009A1 (en) 2021-03-23 2023-10-12 King's College London Compositions comprising nkg2d, cxcr2, and dap10/dap12 fusion polypeptides and methods of use thereof
GB202214120D0 (en) 2022-09-27 2022-11-09 King S College London Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091178A (en) * 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
EP0417193B1 (en) 1988-05-27 1993-08-04 Centocor, Inc. Freeze-dried formulation for antibody products
EP0448605A4 (en) * 1988-12-15 1991-11-21 Invitron Corporation Use of basic amino acids to solubilize immunoglobulins
CA2049342A1 (en) 1989-03-27 1990-09-28 Sally Bolmer Formulations for stabilizing of igm antibodies
US6165467A (en) * 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation
DE69620877T2 (de) * 1995-02-06 2002-12-12 Genetics Inst Arzneimittelformulierungen für il-12
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
CN1151842C (zh) * 1995-07-27 2004-06-02 基因技术股份有限公司 稳定等渗的冻干蛋白制剂
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
DK0999853T3 (da) * 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
KR20120091477A (ko) 1999-03-25 2012-08-17 애보트 게엠베하 운트 콤파니 카게 사람 ｉｌ-12에 결합하는 사람 항체 및 이의 제조방법
PT1324776E (pt) * 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US20030138417A1 (en) * 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies

Also Published As

Publication number Publication date
WO2003039485A3 (en) 2004-02-12
PT1441589E (pt) 2012-08-13
JP2005508981A (ja) 2005-04-07
CN1292655C (zh) 2007-01-03
EP1441589A4 (en) 2007-07-04
KR20050044365A (ko) 2005-05-12
WO2003039485A2 (en) 2003-05-15
AU2002363339B2 (en) 2008-02-07
US20110318343A1 (en) 2011-12-29
IL161677A (en) 2010-06-16
DK1441589T3 (da) 2012-08-06
EP1441589A2 (en) 2004-08-04
EP1441589B1 (en) 2012-05-09
CA2466034C (en) 2012-12-18
JP5290489B2 (ja) 2013-09-18
LU93314I2 (el) 2019-11-20
ATE556591T1 (de) 2012-05-15
US20110070231A1 (en) 2011-03-24
CY2016044I1 (el) 2017-07-12
CA2466034A1 (en) 2003-05-15
US20030138417A1 (en) 2003-07-24
IL161677A0 (en) 2004-09-27
CN1612689A (zh) 2005-05-04
ES2392073T3 (es) 2012-12-04
NZ532896A (en) 2007-08-31
JP2011068675A (ja) 2011-04-07
CY2016044I2 (el) 2017-07-12
KR100913714B1 (ko) 2009-08-24
US8465739B2 (en) 2013-06-18

Similar Documents

Publication Publication Date Title
LU93314I2 (el)
PL406852A1 (pl) Preparat zawierający ludzkie przeciwciała do leczenia zaburzeń związanych z TNF-α
AR104198A2 (es) Formulaciones de proteínas y anticuerpos de alta concentración
EP1409018A4 (en) Stable lyophilized pharmaceutical formulation of IgG antibody
ES2284242T3 (es) Anticuerpos contra il-12 humana.
LU91556I2 (fr) Anticorps humains reconstitués dirigés contre un récepteur de l'interleukine 6 humaine - TOCILIZUMAB
HUP0402653A2 (hu) Interleukin 15-re (IL-15-re) specifikus emberi antitestek
ATE454124T1 (de) Rekombinante anti-cd30-antikörper und deren verwendungen
HRP20120903T1 (hr) Tekuä†a formulacija koja sadrži visoku koncentraciju protutijela
AR099084A2 (es) Composiciones de anticuerpos anti-ctla-4
JP2022535042A (ja) 治療用タンパク質の属性を特定する方法
Ohmori et al. Prostaglandin E2 as a selective stimulator of antigen‐specific IgE response in murine lymphocytes
PT1135158E (pt) Vacinas intensificadas a base de peptidos de imunoglobulina e quimerica
RAINES et al. Antithyrotropin antibodies in the sera of Graves’ disease patients
RU2007133661A (ru) КОМПОЗИЦИИ АНТИТЕЛ К MAdCAM
CY1113904T1 (el) Σταθερο φαρμακευτικο σκευασμα σε υγρη μορφη αντισωματων igg
Thiele et al. Monoclonal and polyclonal antibodies recognizing acetaldehyde–protein adducts
Santana et al. Stability-indicative and conformation-specific enzyme linked immunosorbent assay for analysis of recombinant human gamma interferon
Kayhan et al. Fc‐Dependent Monoclonal IgG1‐Mediated Suppression of Antibody Response
EP1621209A3 (en) Vaccines based on domains of chimeric immunoglobulin E peptides
Kashanian Role of bioactive peptides in autoimmune thyroid disease

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211108